Healthcare Stocks: What Analysts Are Saying About Pfizer and Oneview

Pfizer: Mixed Reviews and Moderate Buy Consensus

• Analyst Rating: Justin Smith from Bernstein maintains a "Hold" rating.
• Price Target: $30.00 (vs. last week's close of $24.79).
• Other Opinions: Another analyst downgrades Pfizer to "Hold" with a price target of $26.00.
• Consensus: "Moderate Buy" with an average price target of $28.40, indicating a potential 13.7% increase from the current stock price.

Oneview Healthcare: Bullish Sentiment Despite Analyst Ranking

• Analyst Rating: Martyn Jacobs from Bell Potter gives a "Buy" rating.
• Price Target: A$0.34 (vs. last week's close of $0.16, the highest in the past year).
• Consensus: "Moderate Buy" with an average price target of $0.23.
• Caution: Jacobs is ranked low among analysts, which may influence investor decisions.

Key Considerations for Investors

• Market Trends: Broader economic conditions and industry performance.
• Company Performance: Individual company metrics and growth prospects.
• Research: Encouraged to conduct thorough research before investing.